Rocket Lab (NASDAQ: RKLB) · Full stock check-up · Snapshot as of market close, September 25, 2026
VERDICT: SELL / TRIM — not a buy at today's price
The bottom line: Rocket Lab is one of the best growth stories in the market — revenue is up more than 60% from a year ago and the company just agreed to buy satellite giant Iridium in an $8 billion deal. But the stock price already assumes almost everything goes right from here. At roughly 50 times sales with no profit yet, you are paying up front for years of flawless execution on a brand-new rocket and a massive, unfinished acquisition. The single biggest factor in our score is valuation — not the business, which we like. The one thing to watch next: whether the company's new, bigger rocket, Neutron, actually reaches the launch pad on schedule this quarter. If you already own shares, consider trimming into strength. If you don't, this is a "watch and wait for a real pullback" stock, not a "buy today" stock.
What Rocket Lab actually does
Rocket Lab builds and launches rockets, and it also builds satellites and satellite parts for other companies and governments. Think of it as a company that both drives the delivery truck (the rocket) and manufactures a lot of what's inside the truck (the satellites and their components).
It has two main businesses today. Launch Services flies its small Electron rocket — it has now flown 97 times — and is finishing a much bigger rocket called Neutron, aimed at the market SpaceX dominates. Space Systems makes satellite parts and whole satellites, and it has grown into the larger of the two businesses, helped along by several recent acquisitions.
And now there's a third act: on June 29, 2026, Rocket Lab agreed to buy Iridium Communications, the company that runs the well-known global satellite phone and data network, for about $8 billion. Iridium shareholders get $54 a share ($27 in cash, the rest in Rocket Lab stock). Iridium's own shareholders approved the deal on September 24, 2026, and Rocket Lab says it has now fully lined up the money to pay for it, including a $1.94 billion stock sale completed on September 15. The deal is expected to close around mid-2027.
This matters enormously for the rest of this report: Iridium made $871.7 million in revenue in 2025 and was solidly profitable (about $114 million in net income). Rocket Lab, by contrast, made $602 million in revenue and lost $198 million. A smaller, unprofitable company is buying a bigger, profitable one — funded with a mix of cash, new debt, and freshly issued stock. That's a bold, high-stakes move, and it colors nearly every section below.
Strengths, weaknesses, opportunities, threats
Strengths
- One of only two Western companies with a proven, repeatedly-flown orbital rocket (97 Electron launches)
- Diversified revenue: launch, satellite manufacturing, and soon satellite services
- Strong balance sheet today — $2.1 billion in cash, very little debt
- Record $2.36 billion order backlog, up 137% from a year ago
Weaknesses
- Still loses money on every dollar of sales (net margin around -21%)
- Neutron, its next big growth engine, has already slipped once and remains unflown
- Free cash flow is deeply negative ($-371 million over the past year)
- Heavy reliance on new stock and debt to fund growth and the Iridium deal
Opportunities
- Iridium adds an immediate, profitable, subscription-like revenue stream and valuable radio spectrum
- Neutron opens a market roughly six times larger per launch than Electron
- Government/defense demand for space is rising sharply (Space Force awards already total $663 million)
- Owning Iridium lets Rocket Lab launch and replace its own satellites, cutting out a middleman
Threats
- A failed or long-delayed first Neutron flight would hit both the stock and the Iridium growth story
- Integrating an $8 billion, larger, culturally different company is genuinely hard
- New debt (a $3.6 billion bridge loan is lined up) changes the risk profile
- The launch and small-satellite market is getting more crowded and competitive
Top 5 risks to keep an eye on
- Execution (Neutron): the rocket has already slipped once; another slip pushes back a key part of the growth story.
- Execution (Iridium integration): folding in a company nearly the size of Rocket Lab itself, plus new debt, is a big operational lift.
- Valuation: the stock already prices in a lot of good news; any stumble could hit the share price hard.
- Regulatory/closing risk: the Iridium deal still needs to close (expected mid-2027); anything that delays or unwinds it would disappoint the market.
- Macro/rate risk: as a high-growth, no-profit stock, RKLB is unusually sensitive to swings in interest rates and investor risk appetite.
Financial health: strong balance sheet, still no profit
Here's the current scorecard, using Rocket Lab's most recent quarterly filing (period ended June 30, 2026) and trailing-twelve-month figures.
| Metric | Value | What it tells you | Grade |
|---|
| P/E ratio | Not meaningful (loss-making) | No earnings yet to divide the price by | F |
| Price / Sales | ~55x trailing revenue | Investors are paying a very rich price for each dollar of sales | D |
| Free cash flow | -$371M (past 12 months) | The business is still burning real cash to grow | F |
| Gross margin | ~37%, expanding | Each new dollar of sales is getting more profitable to deliver | B |
| Operating margin | ~-27% to -29% | Spending on growth still swamps gross profit — expected at this stage, but a real cost | C |
| Return on equity | Roughly -8% to -12% | Currently destroying accounting value per dollar of equity, as expected pre-profitability | D |
| Current ratio | ~5.5x | Plenty of cash and short-term assets to cover near-term bills | A |
| Debt / Equity | ~0.04x (pre-Iridium) | Very little debt today — but this is about to rise a lot once Iridium financing lands | A* |
| Cash & investments | ~$2.1 billion | A large war chest, though a big chunk is earmarked for the Iridium deal | A |
| Dividend yield | None | All cash is being reinvested into growth | — |
*The debt grade reflects today's balance sheet. Rocket Lab has already lined up a $3.6 billion bridge loan plus new stock to help fund the roughly $3+ billion cash portion of the Iridium purchase, so leverage will step up materially once that deal closes.
Overall financial health grade: C+. The company is unusually well-capitalized for a business that still loses money, which buys it time and flexibility — but it is about to take on real debt for the first time in its history.
Growth: the number everyone should focus on
Revenue growth has actually been accelerating, not slowing down, which is rare and worth appreciating.
| Quarter | Revenue | YoY growth | Notes |
|---|
| Q1 2024 | ~$92.7M | — | |
| Q2 2024 | ~$106.3M | — | |
| Q3 2024 | ~$104.8M | — | |
| Q4 2024 | ~$132.4M | — | FY2024 total: $436.2M |
| Q1 2025 | ~$122.6M | +32% | |
| Q2 2025 | $144.5M | +36% | |
| Q3 2025 | ~$154.9M | +48% | |
| Q4 2025 | $180.0M | +36% | Record quarter at the time; FY2025 total: $601.8M |
| Q1 2026 | $200.4M | +63% | Beat estimates by ~5% |
| Q2 2026 | $234.1M | +62% | Record quarter; backlog hit $2.36B |
2024 quarterly splits are compiled from company reports and are approximate; 2025–2026 figures are as reported by the company and SEC filings.
Growth is coming from real, broad-based demand: more Electron launches, and a fast-growing Space Systems business making satellite parts (helped by the Mynaric and Motiv acquisitions). Next quarter's guidance (Q3 2026) is $250–265 million, and the company won't report again until November 9, 2026.
Where does that growth actually come from, and can it continue? Three things are driving it: (1) a steady cadence of roughly 6+ Electron launches a quarter at a reliable price point, (2) satellite-component and full-satellite manufacturing contracts scaling with new customers and past acquisitions, and (3) the beginning of Neutron-related and defense contract revenue (the Space Force has already committed $663 million, though $397 million of that depends on Neutron actually flying). For growth to hold up over the next few years, Neutron needs to start flying on a real cadence (management has guided to roughly 3 flights in 2026, slipping toward late 2026/early 2027, then 5 in 2027, and 7+ a year after that), each one priced at $50–55 million versus roughly $8 million for an Electron launch. If Neutron disappoints, growth doesn't disappear, but it downshifts to whatever the launch-plus-manufacturing business alone can deliver, which is still solid but far less exciting.
Overall earnings-quality and growth grade: B. The growth trend is genuinely strong and broad-based; the main knock is that it still isn't translating into profit or cash generation.
How Rocket Lab stacks up against its closest public peers
| Metric | Rocket Lab (RKLB) | Planet Labs (PL) | AST SpaceMobile (ASTS) | Redwire (RDW) |
|---|
| Market cap | ~$44.3B | ~$13.3B | ~$29B | ~$2.8B |
| Trailing revenue growth | +52.5% | +26% | Triple-digit off a tiny base | +10.3% (FY25); guiding much faster for FY26 |
| Net margin | ~-21% | ~-95% | ~-570% | ~-68% |
| Price / Sales | ~55x | ~40x | ~300x | ~8x |
| Debt / Equity | ~0.04x | Low | ~1.1x | ~0.1–0.2x |
| Dividend yield | None | None | None | None |
Rocket Lab leads this group on the thing that matters most long-term: it is growing quickly at real scale (on a $600–900 million revenue base, not a start-up-sized one), with the strongest balance sheet and the most diversified business of the four. It is not the cheapest of the group on a price-to-sales basis (Redwire is far cheaper; AST SpaceMobile is far more expensive), so its premium looks reasonably earned by its track record — but "reasonably earned" is not the same as "cheap."
Peer comparison grade: B+.
Valuation: this is where the story gets less comfortable
Here's the plain-English version of the most important question in this whole report: what does today's stock price already assume has to go right?
At $73.95 a share, Rocket Lab's market value is about $44 billion — roughly 55 times the revenue it's generated over the past year. For comparison, a "normal" profitable industrial company trades at 1–3 times sales; even a strong, well-loved growth software company usually trades at 8–15 times sales. Rocket Lab's price only makes sense if you believe revenue keeps compounding at a very high rate for many years and that profit margins eventually expand a lot from today's deeply negative levels and that both Neutron and the Iridium integration go smoothly. That's a lot of "and"s.
In plain terms: you are not buying today's Rocket Lab at this price. You are buying a version of Rocket Lab several years from now that has successfully launched Neutron on a regular cadence, successfully absorbed an $8 billion acquisition roughly its own size, and turned solidly profitable — and you're paying for all of that today, in cash, up front.
To be fair to the bulls: Wall Street's average price target is actually above today's price (more on that below), which tells you professional analysts broadly share the growth optimism. Our framework simply weighs valuation and intrinsic value more heavily than sell-side price targets typically do — on purpose, because a rich price with no margin of safety is exactly the kind of setup that can hurt investors when a growth story hits even a minor bump.
Valuation grade: D+.
What is Rocket Lab actually worth? (A simplified discounted cash flow estimate)
A discounted cash flow (DCF) estimate is just a way of asking: "If I add up every dollar of cash this business will ever generate, and adjust for the fact that a dollar next year is worth less than a dollar today, what's the whole thing worth right now?" We built one using Rocket Lab's own guidance and reasonable industry assumptions, run under three scenarios. Note: because the Iridium deal hasn't closed yet, this is built around Rocket Lab's existing launch-and-manufacturing business, with Iridium treated as a separate source of upside once (and if) the deal closes cleanly.
| Bear case | Base case | Bull case |
|---|
| Revenue growth, next 5 years (avg.) | ~15%/yr | ~25%/yr | ~32%/yr |
| Neutron | Further delays, weak cadence | Flies in early 2027, ramps as guided | Flies on schedule, becomes a real Falcon 9 alternative |
| Terminal operating margin | ~12% | ~20% | ~25% |
| Discount rate used | 18% | 16% | 14% |
| Estimated intrinsic value / share | ~$35–40 | ~$68–75 | ~$115–130 |
The current price of $73.95 sits right at the top of our base-case range and roughly double our bear case. That's the core of our caution: there's real upside if the bull case plays out, but not much of a cushion if reality lands anywhere below "everything goes right." A stock discount rate this high (14–18%) reflects Rocket Lab's genuinely high risk profile — its beta (a measure of how much it swings versus the overall market) is about 2.6, meaning it typically moves more than twice as much as the S&P 500 in either direction.
DCF / intrinsic value grade: D+.
Chart check: what the stock's recent trading is telling us
RKLB closed at $73.95 on September 25, 2026, in a 52-week range of $37.57 to $151.00 — itself a sign of how volatile this stock is.
- 50-day average price: roughly $69.50 — the stock is trading a bit above this, a short-term positive sign.
- 200-day average price: roughly $76–78 — the stock is trading right around or just below this longer-term average, a more neutral signal.
- Momentum: shares rallied hard in mid-to-late September, up roughly 19% over two weeks off a local low near $62, suggesting improving short-term momentum after a rough August.
- Volatility: extremely high for a stock of this size — swings of 5–10% in a single day are not unusual around news events.
Directional bias: Neutral-to-Bullish, Medium confidence. The short-term trend has turned up, but the stock is sitting right at a key longer-term resistance level, and the setup could flip quickly on Neutron or Iridium news.
Technical grade: B-.
What Wall Street analysts think
This is the one area where the professional consensus is clearly more upbeat than our own scorecard.
| Metric | Value |
|---|
| Consensus rating | Buy (roughly 14 Buy, 4 Hold, 0 Sell among recently active analysts) |
| Average 12-month price target | ~$109–111 (about 48% above today's price) |
| Highest target | $150 (New Street Research) |
| Lowest target | $47–60 (Goldman Sachs, Wells Fargo) |
| Recent notable moves | Cantor Fitzgerald reiterated an "Overweight" rating with a $122 target in late September, citing the Iridium deal and Neutron as key catalysts; KGI Securities upgraded to Buy in late July |
Why does our own score land more cautiously than the Street average? Sell-side price targets often lean heavily on growth and narrative, and less on strict discounted-value math. Both views are legitimate ways to think about a stock — we're simply flagging that "most analysts like it" and "the price already reflects a lot of good news" can both be true at the same time.
Analyst consensus grade: A-.
What's in the news right now
- Iridium deal fully funded (Sept 15, 2026): Rocket Lab completed a $1.94 billion stock sale to help pay for the acquisition.
- Iridium shareholders approve the deal (Sept 24, 2026): ~99.6% voted in favor — a major milestone, though the deal still needs to close.
- 97th Electron launch (Sept 26, 2026): another successful mission, underscoring the reliability of its core rocket.
- Cathie Wood/ARK Invest has been a steady buyer in recent weeks, a signal of continued institutional growth-investor interest.
- Insider selling: CEO Peter Beck has sold a meaningful number of shares this year — common for founders at this stage, but worth noting.
Media tone is broadly bullish-to-mixed: most coverage frames Rocket Lab as building "a self-launching space superpower" and a real long-term SpaceX challenger, while a growing minority of commentary is starting to ask, openly, whether the price has run ahead of the story. Two tail risks worth watching that aren't fully priced in yet: (1) integration costs or culture clashes from the Iridium deal running higher than expected, and (2) a second Neutron delay landing right before or during the Q4 earnings season.
News & sentiment grade: B+.
Risk assessment
Systematic risk: High. A beta near 2.6 means this stock amplifies whatever the broader market is doing, in both directions.
Liquidity risk: Low. The stock trades roughly 15–30 million shares a day — easy to buy or sell without moving the price much, even in decent size.
Company-specific risk: High. Rocket lab science carries real technical failure risk (any rocket can fail); the Iridium deal adds integration, regulatory, and new-debt risk on top of that; and government-contract concentration cuts both ways — it's a tailwind today but a source of budget-driven uncertainty tomorrow.
Overall risk grade: D+ (elevated). None of these risks are unusual for an ambitious, fast-growing space company — but they are real, and they're stacking up at the same time as the valuation is stretched.
Putting it all together: the final score
| Category | Weight | Score (1–100) | Weighted |
|---|
| Business model & competitive position | 8% | 78 | 6.2 |
| Financial health & ratios | 10% | 55 | 5.5 |
| Earnings quality, trends & growth | 10% | 72 | 7.2 |
| Peer & industry comparison | 7% | 75 | 5.3 |
| Valuation & market-implied expectations | 15% | 40 | 6.0 |
| DCF & intrinsic value | 10% | 42 | 4.2 |
| Technical analysis & momentum | 7% | 65 | 4.6 |
| Analyst consensus & price targets | 7% | 82 | 5.7 |
| News, sentiment & catalysts | 6% | 76 | 4.6 |
| Risk assessment | 10% | 45 | 4.5 |
Weighted score: 53.7 × Macro multiplier: 0.90 (a cautious backdrop) =
48 / 100
Rating band 40–49: SELL · Medium conviction · Trim / reduce exposure
To be clear about what this score means and doesn't mean: it is not a call that Rocket Lab is a bad company, or that it's headed for trouble. It's a statement that, at this specific price, the balance of upside and downside is no longer attractive enough to justify buying more, or starting a new position. A great company and a good stock to buy right now are two different questions, and right now, for Rocket Lab, the answers point in different directions.
Investment verdict
Recommendation: Sell/Trim, Medium conviction. Rocket Lab is a genuinely impressive, fast-growing business with a strong balance sheet and a bold, potentially game-changing acquisition underway. But the stock price already assumes a smooth Neutron debut and a clean Iridium integration — two things that haven't happened yet. The bull case is real (Wall Street mostly agrees with it), but the price leaves very little room for anything to go wrong, and the company is about to take on real debt for the first time. For existing holders, this is a good time to take some profits off the table. For those without a position, this is a "put it on your watchlist and wait for a real pullback" situation, not a "buy today" situation.
Key risk to the thesis: A second meaningful delay to Neutron's first flight (roughly 30–40% probability, in our judgment, given the track record so far) would likely hit the stock hard, since a chunk of both the bull case and the Space Force contract value depends on Neutron actually flying.
What would upgrade this rating: A pullback of 25%+ toward the low-to-mid $50s without a change in the underlying growth story, or clear evidence the Iridium integration is ahead of schedule and margin-accretive.
What would downgrade this rating further: A second Neutron delay past Q1 2027, a renegotiation or collapse of the Iridium deal, or a sustained slowdown in Space Systems bookings.
Key metrics to watch over the next 1–2 quarters:
- Neutron pad delivery/first flight timing — the single biggest near-term catalyst, good or bad.
- Q3 2026 earnings (Nov 9, 2026) — watch whether revenue clears the $250–265M guidance and whether losses keep narrowing.
- Iridium deal progress — regulatory approvals and any updates on the expected mid-2027 close.
- Gross margin trend — needs to keep climbing from ~37% for the bull case to stay intact.
- Insider selling activity — a further pickup would be worth watching.
A simple trading and portfolio plan
Position sizing: Conservative investors, including most retirees, should treat this as a 0–1% "watch" position at most, given the volatility and lack of income. Moderate investors might allow up to 2–3% of a portfolio. Aggressive growth investors who believe strongly in the Neutron/Iridium story might go as high as 5–7%, understanding the real risk of a sharp drawdown.
Entry strategy: Rather than buying at today's price, consider scaling in only on a real pullback — the high-$50s to $60 area would offer a more reasonable margin of safety. Alternatively, wait for confirmation: a decisive, high-volume move above roughly $85–90 would suggest the market is pricing in a clean Neutron pad delivery, which could justify a smaller momentum-based entry.
| Target | Price | Basis |
|---|
| Base case (12 months) | ~$70–75 | Roughly today's price; reflects steady execution, no major surprises |
| Stretch/bull case (18 months) | ~$120–130 | Neutron flies on schedule; Iridium integration goes smoothly |
| Downside/bear case (12 months) | ~$40–45 | Further Neutron delay and/or a bumpy start to Iridium integration |
Stop-loss guidance: A hard, thesis-invalidating level would be a confirmed second major Neutron failure or delay past Q1 2027, or a collapse/major renegotiation of the Iridium deal — technically, a sustained close below the low-$50s would reflect that kind of change. For existing holders simply protecting gains, a trailing stop of roughly 20–25% from recent highs is a reasonable, mechanical way to lock in profits without needing to predict the news.
For income-minded holders: since Rocket Lab pays no dividend, some investors use covered calls (selling call options roughly 15–20% above the current price, 30–45 days out) on existing shares to generate some income while waiting. Others buy protective puts ahead of binary events like the November earnings report or a Neutron launch attempt, to cap downside without selling shares outright. These are options strategies with their own risks and trade-offs, and are best discussed with a licensed advisor if you haven't used them before.
| Scenario | Probability | 12-month return | 18-month return | Impact on a 5% position |
|---|
| Bull case | 20% | +40% | +75% | +2.0 pts |
| Base case | 45% | 0% | +5% | 0.0 pts |
| Bear case | 25% | -40% | -30% | -2.0 pts |
| Severe downside | 10% | -65% | -55% | -3.25 pts |
| Weighted expected return | 100% | Roughly -8% (12-month) |
The main reason for caution isn't the business — it's the price. If Rocket Lab pulls back meaningfully, or if it clears the Neutron and Iridium hurdles cleanly and the market gives you a second chance to buy at a similar multiple, this report's conclusion could change quickly. That's exactly why the "key metrics to watch" section above matters more than the headline rating today.